RayzeBio
Drug Discovery
RayzeBio valuation and funding history | Last updated: September 13, 2022 | 3 funding rounds
Current Valuation
N/A
As of September 13, 2022
Total Funding Raised
N/A
Across 3 rounds
Last Round
Later Stage VC (Series D)
$159.8M
Last Funding
Sep 2022
Funding date
Capital Efficiency
N/A
Valuation / Funding
Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones
| Date | Round | Amount | Post-Valuation | Growth |
|---|---|---|---|---|
| September 13, 2022 | Later Stage VC (Series D) | $159.8M | N/A | - |
| June 8, 2021 | Later Stage VC (Series C) | $108.0M | N/A | - |
| November 30, 2020 | Early Stage VC (Series B) | $105.0M | N/A | - |
Valuation Analysis
Current Valuation Metrics
RayzeBio is currently valued at N/A as of September 13, 2022.
What is RayzeBio Worth in 2026?
RayzeBio is a leading private company in the Drug Discovery sector. Track RayzeBio's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.
How RayzeBio Valuation is Determined
Private company valuations like RayzeBio's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.